- Kristi Powers
Choose the health content that’s right for you, and get it delivered right in your inbox.
AdventHealth physician says it could lead to more treatment options for kidney patients and others

New research, conducted in part at AdventHealth, shows medicines like Ozempic can dramatically reduce the risk of serious illness in people with kidney disease.
“In the near future, this treatment could become one of the pillars of therapy for patients with Type 2 diabetes (T2D) and chronic kidney disease because of the powerful effects this study shows, not just on kidney progression, but on heart disease and mortality,” said Dr. Richard E. Pratley, senior investigator at the AdventHealth Translational Research Institute. “This treatment positively affects multiple organs to decrease risk and this study confirms it’s a whole body, holistic type of treatment. It’s not just a medication focused on lowering blood sugar; it has other major benefits.”
Pratley believes this research supports Ozempic as a life-saving option for a new set of patients. He is the senior author on a recently published study in the New England Journal of Medicine (NEJM) article which looks at the effects of Ozempic in persons with Type 2 diabetes patients with chronic kidney disease.
The trial, called FLOW, evaluated the efficacy and safety of semaglutide (Ozempic) given once weekly in people with T2D and chronic kidney disease from preventing:
- Kidney failure
- Substantial loss of kidney function
- Death from kidney or cardiovascular causes
The groundbreaking study results show promising outcomes and Pratley is confident it will quickly obtain FDA approval, making Ozempic a life-saving option for a new set of patients for whom additional treatment options are badly needed.
“This research shows us where Ozempic’s strengths lie,” Pratley said. “Ozempic has demonstrated efficacy with many of the important complications associated with type 2 diabetes, including heart and kidney disease.”
The study results of over 3,500 participants who were followed for an average of 3.4 years showed:
- 24% lower risk of kidney events worsening kidney function, transplant dialysis, kidney death and cardiovascular disease
- 18% lower risk of major cardiovascular events (heart attack, stroke, etc.)
- 20% lower risk of death
“By sharing these insights with other physicians and clinicians through the NEJM, we hope our findings will eventually become the standard of whole person care globally to improve patient outcomes.”
This is the first study of its kind to examine a GLP-1 receptor agonist (semaglutide) and its effects on kidney outcomes and with promising results, Pratley hopes to drive change in screening for kidney disease.
“There’s a big gap in the number of patients who have kidney disease and the number who are diagnosed,” said Pratley. “Screening needs to start happening with the primary care physician to identify kidney disease in its early stages because we now have treatments that can prevent disease progression.”
In addition to these new findings, there are also other potential benefits of Ozempic being explored, such as improving heart failure in patients and even secondary benefits like improving liver disease and sleep apnea.
Recent News
AdventHealth Zephyrhills continues its commitment to delivering leading-edge cardiovascular care close to home, with the unveiling of its newly renovated Electrophysiology (EP) Lab.
The ICU Vitality Initiative is a program at AdventHealth Littleton that invites former critical patients back to the hospital to visit with the staff who cared for them during their most vulnerable...
We are proud to announce that Dr. Smalley has been officially recognized as a Center of Excellence for the RhinAER nasal procedure by Aerin Medical. This is a prestigious honor held by fewer than 30...
Patients now have greater access to expert lung and sleep care with the arrival of Dr. Martin Alvaro, who is board-certified in pulmonary medicine. He is also a critical care physician with expertise...
AdventHealth is excited to welcome Cindy Thomas, FNP, DNP, to its team at AdventHealth Medical Group Family Medicine at Hendersonville*. Thomas is a board-certified Family Nurse Practitioner. She is...
As a new MedPAC commissioner, AdventHealth's Dr. Diller brings frontline insight to help strengthen Medicare for millions of Americans.
Dr. Smalley has reached an important milestone in her career with her 100th Inspire implant procedure. This accomplishment marks a significant achievement not only for her but also for the patients in...
Community members got to see the critical moments of a stroke emergency, from dialing 911 to receiving lifesaving treatment in the hospital, as part of a live simulation hosted by AdventHealth Ocala.
In 2023, Annie O’Driscoll’s hip pain was so severe, she could barely walk up the stairs without feeling bone crushing pain. This excruciating pain would wake her every hour of the night, leading to...
AdventHealth Fish Memorial is the first in the area to offer incision-free prostate treatment.
Brady specializes in anesthesiology and has practiced with AdventHealth for nearly 27 years.
As part of National EMS week this week, AdventHealth team members from AdventHealth Heart of Florida and Lake Wales hospitals visited EMS/Fire stations in Polk County to deliver gifts and express...